Full side-by-side comparison — 2026
Data as of Sep 10, 2026 · Updated automatically
| Metric | BMY | PFE |
|---|---|---|
| Current Price | 63.42 | 27.57 |
| Previous Close | 63.75 | 27.65 |
| Metric | BMY | PFE |
|---|---|---|
| Trailing P/E | 14.72 | 37.43 |
| Forward P/E | 10.19 | 9.83 |
| Price / Book | 6.12 | 1.90 |
| Price / Sales | 2.78 | 2.55 |
| EV / EBITDA | 9.01 | 8.44 |
| Metric | BMY | PFE |
|---|---|---|
| Dividend Yield | 3.76% | 6.05% |
| Dividend Rate (Annual) | 2.51 | 1.72 |
| 5-Year Avg Yield | 3.55% | 4.48% |
| Payout Ratio | 54.89% | 225.72% |
| Metric | BMY | PFE |
|---|---|---|
| Beta (Volatility) | 0.23 | 0.30 |
| Debt / Equity | 201.86 | 74.25 |
| Quick Ratio | 1.29 | 0.85 |
| Current Ratio | 1.53 | 1.27 |
| Metric | BMY | PFE |
|---|---|---|
| Revenue Growth | 5.70% | 2.60% |
| Earnings Growth | 153.10% | -10.10% |
| Return on Equity | 46.60% | 5.01% |
| Revenue / Share | 24.14 | 11.19 |
| Trailing EPS | 4.54 | 0.76 |
| Forward EPS | 6.56 | 2.90 |
| Metric | BMY | PFE |
|---|---|---|
| Analyst Mean Target | 66.21 | 28.61 |
| Analyst High Target | 80.00 | 35.75 |
| Analyst Low Target | 40.00 | 25.00 |
Bristol-Myers Squibb Company (BMY) leads on 8 of 15 comparable metrics.
This comparison is based on publicly available financial data and is for informational purposes only. It is not investment advice. Past performance does not guarantee future results.
PFE trades at 37.4x earnings vs BMY at 14.7x — a gap this large often reflects different growth expectations, not simple mispricing.
PFE's 6.05% yield looks attractive, but its 225.72% payout ratio signals the dividend may not be sustainable.
BMY carries 202x debt-to-equity — significantly higher than PFE's 74x. High leverage amplifies both gains and losses.
Based on analyst mean price targets. Estimates are not guaranteed and may not reflect future performance.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic …
View BMY details →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, …
View PFE details →Add both to AllInvestView and compare their real-time performance, dividends, and gain/loss side by side.
Start Free Portfolio